Navigating key news stories in pharma

Featured Stories

Featured
Opening the Door: The Technology Scaling the Next Era of Emerging Therapies
Future Biopharma
Opening the Door: The Technology Scaling the Next Era of Emerging Therapies
Future Biopharma

As emerging therapies target increasingly niche genetic pathways, the adoption of AI modeling, organoids, and advanced AAV delivery is becoming essential to ensure successful clinical progression and patient access.

Read More →
Future Biopharma
News
AbbVie Targets Obesity Market with Novel Drug
R&D
AbbVie Targets Obesity Market with Novel Drug
R&D

Phase I trial results for the company’s novel long-acting amylin analog, have demonstrated significant potential for patients to lose up to 9.79% of body weight in 12–13 weeks with no serious adverse events.

Read More →
R&D
Lifecore and Indomo Sign New Deal to Develop Drug–Device Combination Acne Treatment
Dealmaking
Lifecore and Indomo Sign New Deal to Develop Drug–Device Combination Acne Treatment
Dealmaking

Under this new arrangement, the companies will work together to further develop Indomo’s DT-001 candidate, which will be combined with the ClearPen device to allow self-treatment of inflammatory acne lesions.

Read More →
Dealmaking
Opening the Door: The Technology Scaling the Next Era of Emerging Therapies
Future Biopharma
Opening the Door: The Technology Scaling the Next Era of Emerging Therapies
Future Biopharma

As emerging therapies target increasingly niche genetic pathways, the adoption of AI modeling, organoids, and advanced AAV delivery is becoming essential to ensure successful clinical progression and patient access.

Read More →
Future Biopharma

R&D

Featured
AbbVie Targets Obesity Market with Novel Drug
AbbVie Targets Obesity Market with Novel Drug

Phase I trial results for the company’s novel long-acting amylin analog, have demonstrated significant potential for patients to lose up to 9.79% of body weight in 12–13 weeks with no serious adverse events.

NOFLU Consortium Awarded Contract Worth Up to EUR 148 Million
NOFLU Consortium Awarded Contract Worth Up to EUR 148 Million

The funding, which is part of a larger investment commitment from the European Commission, will be used to progress Ethris’ differentiated mRNA vaccine technology as a treatment for pandemic flu.

Preclinical Study Finds Nanotrastuzumab to be Comparable with Herceptin HYLECTA
Preclinical Study Finds Nanotrastuzumab to be Comparable with Herceptin HYLECTA

The nanoparticle suspension formulation was found to mirror the reference product closely in terms of AUC, Cmax, and Tmax across a 21-day Göttingen minipig study performed by Charles River Laboratories.

Novo Nordisk Reveals Headline Phase III Trial Results Evaluating Combination Obesity Treatment
Novo Nordisk Reveals Headline Phase III Trial Results Evaluating Combination Obesity Treatment

The company’s fixed-dose combination treatment demonstrated superior efficacy to its individual components and was shown to be safe and well-tolerated, consisted with other incretin and amylin-based therapies.

Expansion

Featured
Codis Significantly Invests in UK Spray-Drying Capacity for ASDs
Codis Significantly Invests in UK Spray-Drying Capacity for ASDs

With support from LSIMF, Codis is expanding its UK facility with the addition of a GEA PSD-4 commercial-scale spray dryer, making it the only CDMO in the UK to offer such capacity.

ESTEVE Invests Millions into Chicago Facility Expansion
ESTEVE Invests Millions into Chicago Facility Expansion

The major USD 15.5 million upgrade at ESTEVE CDMO’s Morton Grove, Illinois plant, is expected to supercharge small-molecule API production for pharmaceutical and biotech clients across North America.

Eli Lilly Expands U.S. Manufacturing with New Pennsylvania Facility
Eli Lilly Expands U.S. Manufacturing with New Pennsylvania Facility

The USD 3.5 billion site reflects Lilly’s strategy to expand domestic capacity for glucagon-like peptide-1 (GLP‑1) drugs amid soaring demand and supply‑chain scrutiny.

Vetter Commits to New Production Facility in Germany
Vetter Commits to New Production Facility in Germany

The CDMO commits EUR 480 million to a new production facility on its Saarlouis site as it puts into action its long-term growth strategy to meet rising global biopharma demand.

Dealmaking

Featured
Lifecore and Indomo Sign New Deal to Develop Drug–Device Combination Acne Treatment
Lifecore and Indomo Sign New Deal to Develop Drug–Device Combination Acne Treatment

Under this new arrangement, the companies will work together to further develop Indomo’s DT-001 candidate, which will be combined with the ClearPen device to allow self-treatment of inflammatory acne lesions.

Charles River Laboratories Signs Deals to Sell CDMO and Discovery Assets
Charles River Laboratories Signs Deals to Sell CDMO and Discovery Assets

In efforts to streamline its portfolio and prioritize core capabilities, the company has agreed two separate transactions to divest its CDMO and Cell Solutions as well as select European Discovery Services sites.

Joint Venture Between BioDuro and Cenra Set to Increase Commercial API Manufacturing Capacity
Joint Venture Between BioDuro and Cenra Set to Increase Commercial API Manufacturing Capacity

The companies will integrate their strengths from early-stage development and commercial-scale GMP API manufacturing to offer clients an end-to-end API solution.

Company Launches to Accelerate Development of a Novel CGT for Pediatric CP
Company Launches to Accelerate Development of a Novel CGT for Pediatric CP

Kidswell Bio and Treehill Partners have joined forces to create a new company aimed at accelerating the clinical development of a novel SHED stem cell therapy showing early efficacy signals for pediatric cerebral palsy (CP).

Strategy

Featured
Measuring More of What Matters
Measuring More of What Matters

Technological innovations are allowing for improvements in the clinical trial sector and providing greater volumes of data; however, companies should be mindful to ensure they are measuring meaningful data.

Transforming Modern Drug Development with RWE
Transforming Modern Drug Development with RWE

No longer relegated to post-market safety monitoring, RWE is emerging as a critical strategic tool in early drug development, helping to de-risk pipelines, refine target product profiles, and optimize trial design.

Lonza Strengthens Advanced Synthesis Offering
Lonza Strengthens Advanced Synthesis Offering

By fully integrating support for ADC technologies into its Advanced Synthesis portfolio, Lonza is now able to offer phase-appropriate CDMO support for bioconjugates from discovery through clinical supply.

The Delicate Balance Between Innovation and Execution
The Delicate Balance Between Innovation and Execution

When approaching their clinical trials, sponsors need to balance the program’s needs with the tools and approaches they want to implement to ensure success, explains György Barta from Research Professionals.

Future Biopharma

Featured
Opening the Door: The Technology Scaling the Next Era of Emerging Therapies
Opening the Door: The Technology Scaling the Next Era of Emerging Therapies

As emerging therapies target increasingly niche genetic pathways, the adoption of AI modeling, organoids, and advanced AAV delivery is becoming essential to ensure successful clinical progression and patient access.

Transforming the Treatment Landscape with Tailored Therapies
Transforming the Treatment Landscape with Tailored Therapies

Patient outcomes are transforming, thanks to innovative, curative, tailored therapies; however, industry needs to address a few pressing issues to ensure the huge promise of these drugs can be achieved.

Unlocking Potential in Pulmonary and Nasal Drug Delivery
Unlocking Potential in Pulmonary and Nasal Drug Delivery

While advancements are unlocking new possibilities in inhaled drug delivery and the pipeline is strong, the regulatory landscape is still challenging, highlighting the need for specialized partners to unlock future success.

The Role of Artificial Intelligence in Antibody Drug Discovery
The Role of Artificial Intelligence in Antibody Drug Discovery

Traditional antibody discovery is notoriously slow and resource-intensive, but a new wave of AI tools is enabling optimization of candidates prior to them reaching the clinic, accelerating development timelines. 

Regulatory

Featured
Roche's pMN Therapy Meets Primary Endpoint in Phase III Trial
Roche's pMN Therapy Meets Primary Endpoint in Phase III Trial

The company has revealed that its humanized, glycoengineered Type II anti-CD20 mAb has achieved superior complete remission rates versus tacrolimus in the MAJESTY study.

Rilzabrutinib Gains Regulatory Nods in the U.S. and Japan
Rilzabrutinib Gains Regulatory Nods in the U.S. and Japan

The U.S. FDA has granted breakthrough therapy designation and Japan’s MHLW has designated orphan drug status to Sanofi’s BTK inhibitor, rilzabrutinib (Wayrilz), as a treatment for wAIHA.

CBER Issues RTF for Moderna’s Investigational Flu Shot
CBER Issues RTF for Moderna’s Investigational Flu Shot

According to Moderna, the reasoning for the refusal to review the BLA by the regulatory authority is inconsistent with previous feedback, leading the company to request a Type A meeting.

FDA Grants Priority Review of sBLA for Datopotamab Deruxtecan
FDA Grants Priority Review of sBLA for Datopotamab Deruxtecan

If the application is successful, the therapy will become the first-line treatment for patients with unresectable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy.

Upcoming Events

Featured
RNA Leaders World Congress 2026

At RNA Leaders Europe 2026, networking is at the heart of RNA innovation. From focused partnering sessions to casual meetups, every interaction is a chance to build connections in RNA therapeutics, RNA sequencing, and RNA-based technologies.

Paperless Lab Academy® 2026 Europe

It’s a next generation laboratory and scientific informatics event created by life sciences professionals. Join them for hands-on labs, thought leaders’ presentations, workshops, and opportunities to converse, and leave armed with innovative ideas and knowledge.

CDMO Leadership Awards 2026

The 2026 CDMO Leadership Awards are underway, returning during DCAT Week this March in New York. Presented by Outsourced Pharma and Life Science Connect, with independent research conducted by the Tufts Center for the Study of Drug Development, the program recognizes CDMOs based on direct sponsor feedback and peer-reviewed Jury Awards.